Barclays
PACB icon

Barclays’s Pacific Biosciences PACB Stock Holding History

Barclays’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,300
Closed -$149K – 5447
2021
Q4 		$149K Buy
+7,300
New +$176K ﹤0.01% 3640

Other funds holding PACB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bourne Lent Asset Management
Bourne Lent Asset Management Pawling, New York $293M AUM 24.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Carret Asset Management
Carret Asset Management New York $1.14B AUM 25.06% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Barclays's PACB Position: Q3 2026 in Review

Barclays increased its Pacific Biosciences (PACB) stake by 230% in Q3 2026, buying an estimated $899K and bringing the position to 914,004 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

Barclays first reported a position in PACB in Q2 2013 and has held it in 54 quarters since. The position peaked at $6.52M in Q4 2021. 72 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Barclays held 914,004 shares of Pacific Biosciences worth $2.17M as of Q3 2026.
  • Barclays bought 637,016 Pacific Biosciences shares in Q3 2026, an estimated $899K.
  • Pacific Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2542 holding.
  • Barclays first reported a position in Pacific Biosciences in Q2 2013 and has held it in 54 quarters since.
  • Barclays's Pacific Biosciences position peaked at $6.52M in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.